Baqsimi ® (glukagon näspulver)

För fullständig produktresumé för Baqsimi® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Baqsimi® (glukagon näspulver): Användning vid nässjukdomar eller efter näsingrepp eller operationer

Glukagon näspulver har inte studerats för personer med diabetes med diverse nässjukdomar eller som har genomgått näsingrepp eller operationer.

Detailed Information

The NG powder is absorbed passively through the nasal mucosa, and delivery does not require the person to be conscious or to inhale.1,2

NG has not been studied in people with diabetes with nasal conditions such as

  • a deviated septum

  • cribriform plate defect

  • nasal fractures

  • sinusitis

  • dry nasal passages

  • nasal polyps or tumors

  • fibrous nasal papules

  • juvenile angiofibroma

  • nose bleeds

  • nasal bridge issues

  • nasal injuries

  • post nasal drip, or 

  • sleep apnea.

NG has not been studied in people with diabetes who have undergone nasal procedures or surgeries such as

  • rhinoplasty

  • septoplasty

  • rhinoseptoplasty

  • turbinectomy

  • turbinoplasty, or 

  • sinus surgery.

NG is designed to be absorbed in the nasal cavity. It is unknown what impact may be seen on the efficacy and safety of NG in people with these nasal conditions or who have undergone and recovered from these nasal procedures or surgeries.

A person with any nasal condition or who has undergone any nasal procedure or surgery should have a further discussion with their health care provider on the use of NG.

Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacokinetics via the nasal route.3

Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacodynamics of NG.3

References

1. Rickels MR, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264-270. https://doi.org/10.2337/dc15-1498

2. Sherr JL, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555-562. https://doi.org/10.2337/dc15-1606

3. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

NG = nasal glucagon (glucagon nasal powder)

PD = pharmacodynamic

PK = pharmacokinetic

Datum fӧr senaste ӧversyn 2019 M11 07


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss